Item 1.01. Entry into a Material Definitive Agreement.

On May 5, 2020, Rennova Health, Inc. (the "Company") entered into an Exchange Agreement (the "Agreement") with Alcimede LLC ("Alcimede"), of which Seamus Lagan, our Chief Executive Officer, is the sole manager. Pursuant to the Agreement, the Company issued to Alcimede 250,000 shares of its Series L Convertible Preferred Stock (the "Series L Preferred Stock") in exchange for the 250,000 shares of the Company's Series K Convertible Preferred Stock (the "Series K Preferred Stock") held by Alcimede. The Series K Preferred Stock had been issued to Alcimede on December 23, 2019 and upon the issuance of the Series L Preferred Stock to Alcimede, the shares of Series K Preferred Stock were cancelled. Shares of the Series K Preferred Stock were convertible immediately into common stock and were entitled to receive, when and as declared by the Board of Directors, dividends equal (on an as if converted to common stock basis) to and in the same form as dividends actually paid on shares of common stock. As previously disclosed, the Series L Preferred Stock is not convertible into common stock prior to December 1, 2020 and is not entitled to receive any dividends.

The foregoing description of the Agreement does not purport to be complete and is qualified by reference to the Agreement, a copy of which is filed as Exhibit 10.178 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits



Exhibit No.   Exhibit Description

10.178          Exchange Agreement, dated as of May 5, 2020, between Rennova
              Health, Inc. and Alcimede LLC




2

© Edgar Online, source Glimpses